Terms: = Prostate cancer AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP AND Treatment
303 results:
1. [Drastic changes in the treatment of metastatic prostate cancer].
Thellenberg Karlsson C; Ståhl O
Lakartidningen; 2024 Apr; 121():. PubMed ID: 38651316
[TBL] [Abstract] [Full Text] [Related]
2. Population-based BRCA germline mutation screening in the Han Chinese identifies individuals at risk of BRCA mutation-related cancer: experience from a clinical diagnostic center from greater Shanghai area.
Wu Z; Zhang Q; Jin Y; Zhang X; Chen Y; Yang C; Tang X; Jiang H; Wang X; Zhou X; Yu F; Wang B; Guan M
BMC Cancer; 2024 Apr; 24(1):411. PubMed ID: 38566028
[TBL] [Abstract] [Full Text] [Related]
3. cancer trend and radiotherapy utilization at a tertiary academic hospital in Malaysia.
Gan DEH; Bustam AZ
J Cancer Res Ther; 2024 Jan; 20(1):358-362. PubMed ID: 38554346
[TBL] [Abstract] [Full Text] [Related]
4. [Molecular testing of prostate cancer: timing, methods and consequences].
von Amsberg G; Paulsen FO
Aktuelle Urol; 2024 Apr; 55(2):123-133. PubMed ID: 38537659
[TBL] [Abstract] [Full Text] [Related]
5. Ductal, intraductal, and cribriform carcinoma of the prostate: Molecular characteristics and clinical management.
Shi Y; Wang H; Golijanin B; Amin A; Lee J; Sikov M; Hyams E; Pareek G; Carneiro BA; Mega AE; Lagos GG; Wang L; Wang Z; Cheng L
Urol Oncol; 2024 May; 42(5):144-154. PubMed ID: 38485644
[TBL] [Abstract] [Full Text] [Related]
6. Abrogation of KLF5 sensitizes
Zhang Z; Liu Y; Xu Y; Xu Z; Jia J; Jin Y; Wang W; Liu L
Acta Biochim Biophys Sin (Shanghai); 2024 Apr; 56(4):576-585. PubMed ID: 38433576
[TBL] [Abstract] [Full Text] [Related]
7. Precision Medicine in Castration-Resistant prostate cancer: Advances, Challenges, and the Landscape of PARPi Therapy-A Narrative Review.
Dimitrov G; Mangaldzhiev R; Slavov C; Popov E
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396858
[TBL] [Abstract] [Full Text] [Related]
8. Combined Cabazitaxel and Carboplatin treatment of Metastatic Castration Resistant prostate cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy.
van der Zande K; Tutuhatunewa-Louhanepessy RD; Hamberg P; Ras S; de Feijter JM; Dezentjé VO; Broeks A; Cornelissen S; Beeker A; van der Noort V; Zwart W; Bergman AM
Clin Genitourin Cancer; 2024 Apr; 22(2):445-453.e1. PubMed ID: 38246830
[TBL] [Abstract] [Full Text] [Related]
9. Predictive and prognostic biomarkers in urological tumours.
Cimadamore A; Franzese C; Di Loreto C; Blanca A; Lopez-Beltran A; Crestani A; Giannarini G; Tan PH; Carneiro BA; El-Deiry WS; Montironi R; Cheng L
Pathology; 2024 Mar; 56(2):228-238. PubMed ID: 38199927
[TBL] [Abstract] [Full Text] [Related]
10. A novel targeted NGS panel identifies numerous homologous recombination deficiency (HRD)-associated gene mutations in addition to known BRCA mutations.
Vogel A; Haupts A; Kloth M; Roth W; Hartmann N
Diagn Pathol; 2024 Jan; 19(1):9. PubMed ID: 38184614
[TBL] [Abstract] [Full Text] [Related]
11. Prevalence of germline brca1/2 pathogenic variants in Japanese patients treated with castration-resistant prostate cancer and efficacy of CRPC treatment in real-world clinical practice.
Maekawa S; Takata R; Sekiguchi K; Kagabu M; Toyoshima M; Tamada S; Takahashi K; Ikarashi D; Matsuura T; Kato R; Kato Y; Kanehira M; Sugimura J; Abe T; Baba T; Obara W
Jpn J Clin Oncol; 2024 Apr; 54(4):489-497. PubMed ID: 38157885
[TBL] [Abstract] [Full Text] [Related]
12. Pilot Trial of Streamlined Genetic Education and Traceback Genetic Testing in prostate cancer Survivors.
Schwartz MD; Peshkin BN; Isaacs C; Grisham C; Holmes NJ; Sorgen LJ; Collins S; Dawson N; McGuire C; Okobi T; Newell K; Kolla KA; Weinstein V
J Natl Compr Canc Netw; 2023 Dec; 21(12):1261-1268.e14. PubMed ID: 38081141
[TBL] [Abstract] [Full Text] [Related]
13. Determining magnitude of benefit from poly(ADP-ribose) polymerase inhibitors in prostate cancer.
Akbıyık I; Ürün Y
Future Oncol; 2023 Dec; 19(39):2585-2591. PubMed ID: 38073492
[TBL] [Abstract] [Full Text] [Related]
14. Review of the Developing Landscape of prostate Biopsy and Its Roles in prostate cancer Diagnosis and treatment.
Okubo Y; Sato S; Terao H; Yamamoto Y; Suzuki A; Hasegawa C; Yoshioka E; Ono K; Washimi K; Yokose T; Nakaigawa N; Kishida T; Miyagi Y
Arch Esp Urol; 2023 Nov; 76(9):633-642. PubMed ID: 38053418
[TBL] [Abstract] [Full Text] [Related]
15. brca1/2 reversion mutations in a pan-cancer cohort.
Nakamura K; Hayashi H; Kawano R; Ishikawa M; Aimono E; Mizuno T; Kuroda H; Kojima Y; Niikura N; Kawanishi A; Takeshita K; Suzuki S; Ueno S; Okuwaki K; Sasaki J; Yamaguchi M; Masuda K; Chiyoda T; Yamagami W; Okada C; Nohara S; Tanishima S; Nishihara H
Cancer Sci; 2024 Feb; 115(2):635-647. PubMed ID: 38041241
[TBL] [Abstract] [Full Text] [Related]
16. DNA Damage Response and Mismatch Repair Gene Defects in Advanced and Metastatic prostate cancer.
Akhoundova D; Francica P; Rottenberg S; Rubin MA
Adv Anat Pathol; 2024 Mar; 31(2):61-69. PubMed ID: 38008971
[TBL] [Abstract] [Full Text] [Related]
17. Olaparib for the treatment of Patients With Metastatic Castration-Resistant prostate cancer and Alterations in
Mateo J; de Bono JS; Fizazi K; Saad F; Shore N; Sandhu S; Chi KN; Agarwal N; Olmos D; Thiery-Vuillemin A; Özgüroğlu M; Mehra N; Matsubara N; Young Joung J; Padua C; Korbenfeld E; Kang J; Marshall H; Lai Z; Barnicle A; Poehlein C; Lukashchuk N; Hussain M
J Clin Oncol; 2024 Feb; 42(5):571-583. PubMed ID: 37963304
[TBL] [Abstract] [Full Text] [Related]
18. Platinum-based chemotherapy in metastatic prostate cancer: what possibilities?
Catalano M; Lapucci A; Nobili S; De Gennaro Aquino I; Vascotto IA; Antonuzzo L; Villari D; Nesi G; Mini E; Roviello G
Cancer Chemother Pharmacol; 2024 Jan; 93(1):1-9. PubMed ID: 37934252
[TBL] [Abstract] [Full Text] [Related]
19. Is It Time to Anticipate the Use of PARP Inhibition in prostate cancer Patients?
Sciarra A; Santarelli V; Santodirocco L; Frisenda M; Salciccia S; Casale P; Forte F; Mariotti G; Moriconi M; Cattarino S; Sciarra B; Bevilacqua G; Gentilucci A
Curr Oncol; 2023 Aug; 30(9):8054-8067. PubMed ID: 37754499
[TBL] [Abstract] [Full Text] [Related]
20. Efficacy and safety of PARP inhibitors in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis of clinical trials.
Iannantuono GM; Chandran E; Floudas CS; Choo-Wosoba H; Butera G; Roselli M; Gulley JL; Karzai F
Cancer Treat Rev; 2023 Nov; 120():102623. PubMed ID: 37716332
[TBL] [Abstract] [Full Text] [Related]
[Next]
